Taieb, J, Fakih, M, Salvatore, L, Esaki, T, Modest, DP, Paez, D, Karamouzis, MV, Ruiz, E, Kim, TW, Kuboki, Y, Meriggi, FA, Cunningham, D, Yeh, KH, Cremolini, C, Wang, J, Tran, Q, Chao, J, Chen, Z, Pietrantonio, F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.043. PMID:. IF:65.400(Q1/1D).

John, T, Grohe, C, Goldman, JW, Kato, T, Laktionov, KK, Bonanno, L, Tiseo, M, Majem, M, Domine, M, Ahn, MJ, Perol, M, Hartmaier, R, Robichaux, J, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Herbst, RS, Tsuboi, M, Wu, YL. Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Guerrero, A, Alvarez, I, Novoa, SA, Jurado, JC, Sanchez, CAR, Martinez, P, Falo, C, Hernández-Sosa, M, Margelí, M, Maeso, IG, Rodríguez-Lescure, A, Alcalá, MM, Anton, A, Ferreiro, SV, Herranz, J, Caballero, R, García, DF, Tibau, A, Cobo, SLT, Todo, FGR. Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

González-Lopez, JA, Sebio, A, Hindi, N, Jimenez, M, Villarejo-Campos, P, Martin-Broto, J, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Gimenez-Salinas, LK, Garcia, JAT, Campos, AP, Lopera, E, Bertran, J, Pousa, AL. First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Garassino, MC, Wakelee, HA, Spicer, J, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Chen, KN, Dooms, CA, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Rodriguez-Abreu, D, Chaft, JE, Yang, J, Arunachalam, A, Norquist, JM, Keller, SM, Gao, SG. Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Soler, RS, Vivas, CS, Macias, I, Esteban, AY, Bassam, A, Plazas, JG, Al-Farhat, Y, Cervantes, A, Alfonso, PG, Paez, D, Ruiz-Casado, A, Lopez, C, Arkosy, PF, Furka, A, Rodriguez-Salas, N, Pascual, FJR, Gracian, AC, Hitre, E, Monteagudo, RF, Salvia, MAS. Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.020. PMID:. IF:65.400(Q1/1D).

Tibau, A, Hwang, TJ, Molto, C, Avorn, J, Kesselheim, AS. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies. JAMA Oncology. 2024; 10(5)DOI:10.1001/jamaoncol.2024.0194. PMID:38573645. IF:20.100(Q1/1D).

Salazar, J, Garcia-Planella, E, Fernández-Clotet, A, Esteve, M, Gisbert, JP, Busquets, D, Lucendo, A, Márquez, L, Guardiola, J, Martín-Arranz, MD, Iglesias, E, Monfort, D, Villoria, A, Cañete, F, Bell, O, Ricart, E, Zabana, Y, Chaparro, M, Domènech, E, Gordillo, J. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024; 90(5)DOI:10.1111/bcp.16017. PMID:38369687. IF:3.000(Q2/4D).

Anguera, G, Mulet, M, Zamora, C, Osuna-Gómez, R, Barba, A, Sullivan, I, Serra-López, J, Cantó, E, Vidal, S, Majem, M. Potential Role of Circulating PD-L1⁺ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients. Biomedicines. 2024; 12(5)DOI:10.3390/biomedicines12050958. PMID:38790920. IF:3.900(Q1/3D).

Alserawan, L, Mulet, M, Anguera, G, Riudavets, M, Zamora, C, Osuna-Gómez, R, Serra-López, J, Joaquín, AB, Sullivan, I, Majem, M, Vidal, S. Kinetics of IFN?-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors. Cancers. 2024; 16(9)DOI:10.3390/cancers16091759. PMID:38730712. IF:4.400(Q2/3D).

Riudavets, M, Auclin, E, Mosteiro, M, Dempsey, N, Majem, M, Prelaj, A, López-Castro, R, Bosch-Barrera, J, Pilotto, S, Escalera, E, Tagliamento, M, Mosquera, J, Zalcman, G, Nana, FA, Ponce, S, Albarrán-Artahona, V, Dal Maso, A, Spotti, M, Mielgo, X, Mussat, E, Reyes, R, Benítez, JC, Lupinacci, L, Duchemann, B, De Giglio, A, Blaquier, JB, Audigier-Valette, C, Scheffler, M, Nadal, E, Lopes, G, Signorelli, D, Garcia-Campelo, R, Menis, J, Bluthgen, V, Campayo, M, Recondo, G, Besse, B, Mezquita, L, Planchard, D. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2024; 25(3)DOI:10.1016/j.cllc.2023.11.007. PMID:38105153. IF:3.300(Q2/4D).

Torres-Esquius, S, Llop-Guevara, A, Gutiérrez-Enríquez, S, Romey, M, Teulé, A, Llort, G, Herrero, A, Sánchez-Henarejos, P, Vallmajó, A, González-Santiago, S, Chirivella, I, Cano, JM, Graña, B, Simonetti, S, de Corcuera, ID, Cajal, TRY, Sanz, J, Serrano, S, Otero, A, Churruca, C, Sánchez-Heras, AB, Servitja, S, Guillén-Ponce, C, Brunet, J, Denkert, C, Serra, V, Balmaña, J. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Network Open. 2024; 7(4)DOI:10.1001/jamanetworkopen.2024.7811. PMID:38648056. IF:9.700(Q1/1D).

Lubinski, J, Kotsopoulos, J, Moller, P, Pal, T, Eisen, A, Peck, L, Karlan, BY, Aeilts, A, Eng, C, Bordeleau, L, Foulkes, WD, Tung, N, Couch, FJ, Fruscio, R, Cajal, T, Singer, CF, Neuhausen, SL, Zakalik, D, Cybulski, C, Gronwald, J, Huzarski, T, Stempa, K, Dungan, J, Cullinane, C, Olopade, OI, Metcalfe, K, Sun, P, Narod, SA. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 2024; DOI:10.1001/jamaoncol.2023.6944. PMID:38421676. IF:20.100(Q1/1D).

Motzer, RJ, Porta, C, Eto, M, Powles, T, Gruenwald, V, Hutson, TE, Alekseev, B, Rha, SY, Merchan, J, Goh, JC, Lalani, AKA, De Giorgi, U, Melichar, B, Hong, SH, Gurney, H, Mendez-Vidal, MJ, Kopyltsov, E, Tjulandin, S, Gordoa, TA, Kozlov, V, Alyasova, A, Winquist, E, Maroto, P, Kim, M, Peer, A, Procopio, G, Takagi, T, Wong, SR, Bedke, J, Schmidinger, M, Rodriguez-Lopez, K, Burgents, J, He, CX, Okpara, CE, Mckenzie, J, Choueiri, TK. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(11)DOI:10.1200/JCO.23.01569. PMID:38227898. IF:41.900(Q1/1D).

Rofes, P, Dueñas, N, del Valle, J, Navarro, M, Balmaña, J, Ramón y Cajal, T, Tuset, N, Castillo, C, González, S, Brunet, J, Capellá, G, Lázaro, C, Pineda, M. Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation. Cancer Medicine. 2024; 13(7)DOI:10.1002/cam4.7041. PMID:38558366. IF:3.100(Q2/5D).

Rueda, AG, Taus, A, Alvarez, RA, Bernabé-Caro, R, Chara, L, López-Brea, M, Vilà, L, González, MAS, Aldagalán, ADD, Herrera, BE, Castro, RL, Cabellos, RA, Doménech, M, Falagan, S, Vega, AM, Aguado, C, Barba, A, Ureña, MTD, Isla, D, Hernández, LB, Pérez, JLF, Juan-Vidal, O, Massuti, B, Mielgo-Rubio, X, Ortega, AL, Catot, S, Dómine, M, Escoín-Pérez, C, Navalón, FG, Gil-Bazo, I, Muñoz, S, Rodríguez-Abreu, D, Roldán, RMV, Curbera, GA, León-Mateos, L, Padilla, A, Lario, AP, Sánchez-Torres, JM, Garrido, P. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical & Translational Oncology. 2024; 26(9)DOI:10.1007/s12094-024-03404-9. PMID:38512450. IF:2.500(Q3/6D).

Di Giacomo, AM, Schenker, M, Medioni, J, Mandziuk, S, Majem, M, Gravis, G, Cornfeld, M, Ranganathan, S, Lou, S, Csoszi, T. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). ESMO Open. 2024; 9(3)DOI:10.1016/j.esmoop.2024.102387. PMID:38401247. IF:8.300(Q1/2D).

Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, CX, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023). Frontiers in Oncology. 2024; 13DOI:10.3389/fonc.2023.1343027. PMID:38495081. IF:3.300(Q2/4D).

Day, E, Gavira, J, Tapia, JC, Anguera, G, Maroto, P. What About Variant Histologies in Bladder Cancer?. European Urology Focus. 2024; 10(2)DOI:10.1016/j.euf.2024.05.015. PMID:38849276. IF:5.600(Q1/1D).

Schreurs, MAC, Cajal, TRY, Adank, MA, Collee, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. BREAST. 2024; 73DOI:10.1016/j.breast.2023.103611. PMID:38039887. IF:7.900(Q1/1D).